Contents

Chapter 1  Introduction

Chapter 2  New treatment options for patients with metastatic prostate cancer: What is the optimal sequence?

Chapter 3  Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF transduced allogeneic prostate cancer cells

Chapter 4  Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: A systematic review

Chapter 5  A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial)

Chapter 6  A randomized phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone: the Taxium II trial

Chapter 7  A phase I trial of cabazitaxel combined with rhenium-188-HEDP in patients with metastatic castration-resistant prostate cancer who progressed on or after a docetaxel containing treatment: the ReCab trial

Chapter 8  Summarizing discussion and future perspectives

Addendum
Nederlandse samenvatting
List of abbreviations
List of publications
Curriculum vitae
Dankwoord